Overview Request Sample Pages Request Customization Download PDF
You are viewing: US Veterinary Biologics Market analysis
Part of: Veterinary Biologics Market (Global)

The US Veterinary Biologics Market was valued at $774.53 Million in 2025 and projected to reach to $1040.41 Million by 2030, representing a compound annual growth rate of 6.1%. The US veterinary biologics market is positioned for sustained expansion driven by demographic shifts in pet ownership and increased spending on animal healthcare.

US Veterinary Biologics Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Veterinary Biologics Market Trends and Insights

  • The US market is driven by increasing pet ownership, rising demand for preventive healthcare in companion animals, and growing adoption of advanced immunological therapies across livestock and equine sectors.
  • In 2025, the US represents a significant portion of North American veterinary biologics demand, supported by strong regulatory frameworks and high veterinary spending per capita. By 2030, the US veterinary biologics market is expected to grow at a compound annual growth rate of 6.1%, outpacing global expansion trends.
  • The US market benefits from technological innovation in vaccine development, expansion of biologics for chronic disease management, and increased investment in animal health infrastructure.
  • Regulatory clarity from the USDA and FDA continues to support product approvals and market entry, positioning the US as a leader in veterinary biologics adoption and innovation through the forecast period..

Key Market Statistics

  • CAGR (2025-2030) 6.1% CAGR
  • Market Size, 2025 ~USD 774.53 Million
  • Forecast, 2030 ~USD 1040.41 Million
  • Country US

US Veterinary Biologics Market Overview

Market Valuation Growth :

The US veterinary biologics market is valued at $774.53 million in 2025 and is projected to reach $1,040.41 million by 2030, representing a robust 6.1% CAGR over the forecast period.

Pet Ownership Surge :

Increasing pet ownership across the US is driving demand for preventive healthcare solutions, with companion animal biologics becoming a significant revenue driver for the market.

Livestock & Equine Expansion :

Growing adoption of advanced immunological therapies in livestock and equine sectors is expanding the market beyond companion animals, creating new revenue opportunities for biologics manufacturers.

Preventive Healthcare Trend :

Rising consumer awareness of preventive healthcare in animals is shifting purchasing patterns toward biologics-based solutions, supporting sustained market growth through 2030.

US Veterinary Biologics Market Dynamics

  • Companion animals continue to represent the largest segment, with owners increasingly investing in preventive care solutions including vaccines and immunotherapies.
  • The livestock and equine sectors are emerging as high-growth areas, with farmers and veterinarians adopting advanced biologics to improve herd health and productivity.
  • Regulatory support and product innovation are expected to accelerate market penetration across all animal categories through 2030..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Key Takeaways

    • The US veterinary biologics market is valued at $774.53 million in 2025 and will reach $1,040.41 million by 2030, representing a 6.1% CAGR.
    • The US market is driven by rising pet ownership, preventive healthcare demand, and advanced immunological therapy adoption across companion and production animals.
    • The US benefits from strong regulatory support and high veterinary spending, positioning it as a leader in veterinary biologics innovation and market adoption.
    • By 2030, the US market will experience accelerated growth through vaccine innovation, chronic disease management biologics, and expanded animal health infrastructure investment.

    Veterinary Biologics Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CANINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 5.2% from 2025 to 2030
    Largest Segment INJECTABLE ROUTE OF ADMINISTRATION (Route Of Administration)
    Market Size Base Year (Billions) ~USD 2.72 (2025)
    Revenue Forecast (Billions) ~USD 3.51 (2030)
    Segments Covered Product Type, Animal Type, Type, Route Of Administration, Application, End User

    US Veterinary Biologics Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Product Type

    • Diagnostic Kits
    • Immunodmodulators & Immunostimulants
    • Immunoglobulins & Antitoxins
    • Immunomodulators & Immunostimulants
    • Immuoglobulins & Antitoxins
    • Monoclonal Anitbodies
    • Monoclonal Antibodies

    By Animal Type

    • Companion Animal
    • Companion Animals
    • Livestock Animal
    • Livestock Animals

    By Type

    • Bovine
    • Canine
    • Equine
    • Feline
    • Intramuscular Route Of Administration
    • Intravenous Route Of Administration
    • Other Injectable Route Of Administration
    • Porcine
    • Poultry
    • Small Ruminant
    • Subcutaneous Route Of Administration

    By Route Of Administration

    • Injectable Route Of Administration
    • Oral Route Of Administration
    • Other Routes Of Administration

    By Application

    • Dermatology
    • Diagnostic Testing
    • Diagnostic Tetsing
    • Infectious Disease Prevention
    • Oncology
    • Other Applications
    • Pain Management

    By End User

    • Other End Users
    • Veterinary Diagnostic Labs
    • Veterinary Hospitals & Clinics

    US: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    OTHER END USERS53.0554.4956.157.9359.9462.1964.7467.463.8
    VETERINARY DIAGNOSTIC LABS314.99326.02338.22351.91366.9383.61402.39422.494.6
    VETERINARY HOSPITALS & CLINICS759.82799.22842.58890.92943.911002.910691140.526.2
    TOTAL1127.861179.731236.91300.761370.741448.71536.131630.475.7

    Target Audience

    • Veterinary Biologics Manufacturers : Need US market data to assess market opportunity, benchmark performance, and develop product commercialization strategies tailored to American veterinary practices and animal owners.
    • Investment & Private Equity Firms : Require detailed US market metrics and growth projections to evaluate investment opportunities in veterinary biologics companies and identify acquisition targets in the American market.
    • Veterinary Distributors & Retailers : Need segment-specific demand forecasts and adoption trends for the US to optimize inventory management, supplier relationships, and sales strategies across companion and livestock channels.
    • Animal Health Consultants : Require comprehensive US market analysis to advise clients on market positioning, competitive strategies, and growth opportunities within the American veterinary biologics sector.
    • Regulatory & Policy Advisors : Need US-specific market intelligence to understand adoption patterns, stakeholder needs, and market dynamics to inform regulatory recommendations and policy development.

    Key Companies in the US Veterinary Biologics Market

    CompanyHQOwnershipStrongest segments
    IDEXXUnited StatesPublic CompanyCompanion Animal Group (in-clinic diagnostics, reference labs, services, software),Water Quality Products,Livestock, Poultry and Dairy (including related diagnostics),
    ELANCOUnited StatesPublic CompanyCompanion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal),Companion animal vaccines and therapeutics (Galliprant, Atopica, Milbemax, Onsior, Tru Family),Farm animal feed additives and productivity enhancers (Rumensin, Experior, Hemicell, Surmax, Pulmotil),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations),Vaccines (Gardasil, pediatric and adult vaccines including Vaxneuvance, Capvaxive),Cardiovascular, pulmonary hypertension and specialty (Winrevair, Adempas/Verquvo, Ohtuvayre, others),
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    NEOGEN CORPORATIONUnited StatesPublic CompanyFood Safety diagnostics, media, and sanitation,Animal Safety instruments, care products, and biosecurity,Genomics services for livestock and companion animals,
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Systems,Life Science Reagents and Consumables,
    IMMUCELL CORPORATIONUnited StatesPublic CompanyFirst Defense (core scours prevention),Tri-Shield First Defense,Dual-Force First Defense and related formulations,

    IDEXX

    IDEXX is a public company founded in 1983 and headquartered in the United States, employing 11,000 people.

    ELANCO

    Elanco is a public company founded in 1954 in the United States with 9,650 employees.

    MERCK & CO., INC.

    Merck & Co., Inc. is a public pharmaceutical company founded in 1891 and based in the United States, with 74,000 employees.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a public company founded in 1956 in the United States and employs 125,000 people.

    NEOGEN CORPORATION

    Neogen Corporation is a public company founded in 1981 in the United States with 2,974 employees.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States and employs 7,450 people.

    IMMUCELL CORPORATION

    ImmuCell Corporation is a public company founded in 1982 in the United States with 73 employees.

    Reasons to Buy this Report

    • Market Size & Growth Data : Access precise valuation metrics for the US market with 2025 baseline ($774.53M) and 2030 forecast ($1,040.41M), enabling accurate financial planning and investment decisions.
    • Segment-Specific Insights : Understand performance across companion animals, livestock, and equine sectors with US-focused analysis to identify high-growth opportunities and market gaps.
    • Competitive Landscape Intelligence : Gain detailed understanding of US market dynamics, key players, and competitive positioning to inform product development and market entry strategies.
    • Regulatory & Adoption Trends : Stay informed on US regulatory environment, veterinary adoption rates, and consumer behavior patterns specific to American pet owners and agricultural stakeholders.
    • Strategic Planning Support : Leverage US-specific forecasts and trend analysis to develop targeted marketing strategies, pricing models, and distribution approaches for the American veterinary market.

    Frequently asked questions

    What is the current size of the US veterinary biologics market in 2025?

    The US veterinary biologics market is valued at $774.53 million in 2025, reflecting strong demand for immunological therapies and vaccines across companion and production animal segments.

    What is the projected size of the US veterinary biologics market by 2030?

    The US veterinary biologics market is projected to reach $1,040.41 million by 2030, growing at a compound annual growth rate of 6.1% from 2025 to 2030.

    What are the primary drivers of growth in the US veterinary biologics market?

    Key growth drivers in the US include increasing pet ownership, rising demand for preventive animal healthcare, adoption of advanced immunological therapies, and strong regulatory support from the USDA and FDA.

    How does the US veterinary biologics market compare to global growth rates?

    The US market is growing at 6.1% CAGR, which outpaces the global veterinary biologics market growth rate of 5.2%, indicating stronger demand and market maturity in the United States.

    What factors will support US veterinary biologics market expansion through 2030?

    The US market will be supported by continued vaccine innovation, expansion of biologics for chronic disease management, increased animal health infrastructure investment, and sustained high veterinary spending per capita.

    RESEARCH METHODOLOGY

    This study extensively used both primary and secondary sources. The research process examined various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, market dynamics, and strategies of major players.

    Secondary Research

    This research involved the use of comprehensive secondary sources, including directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was employed to gather information for an extensive, technical, market-focused, and commercial analysis of the veterinary biologics market. It also helped obtain crucial details about key players, market classification, and segmentation based on industry trends at the most detailed levels, as well as significant developments related to market and technology perspectives. Additionally, a database of major industry leaders was created using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources from the supply side include project managers, sales managers, marketing managers, business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary biologics market. Primary sources from the demand side consist of professionals from veterinary hospitals and clinics, diagnostic labs, academic and research institutes, and pet owners.

    A breakdown of the primary respondents is provided below:

    Veterinary Biologics Market

    Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

    Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

    Source: MarketsandMarkets Analysis

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The total size of the veterinary biologics market was determined through data triangulation from three different approaches, as outlined below. After each approach, a weighted average was calculated based on the level of assumptions used in each method.

    Veterinary Biologics Market

    Data Triangulation

    After defining the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown methods were used where applicable to complete the overall market analysis and determine accurate statistics for all segments and subsegments. The following figure illustrates the market validation, source structure, and data triangulation approach used in the market analysis process.

    Market Definition

    The veterinary biologics market includes all USDA-regulated biologic products, such as monoclonal antibodies, immunoglobulins, immunomodulators, and diagnostic kits, which are used for the prevention, diagnosis, or treatment of animal diseases. These products serve companion animals, livestock, and poultry across veterinary clinics, hospitals, diagnostic labs, and farm or herd settings, enabling veterinarians and animal health professionals to provide targeted immune-based interventions and rapid diagnostic testing. This allows infected animals to be identified quickly for faster treatment, containment, or herd management decisions.

    Stakeholders

    • Veterinary Biologics Manufacturers
    • Animal Healthcare Product Manufacturers
    • Veterinary Biologics Distributors and Wholesalers
    • Animal Welfare Associations
    • Veterinary Clinics and Care Centers
    • Research And Consulting Firms
    • Veterinary Research and Development Organizations
    • Contract Manufacturing Organizations
    • Venture Capitalists

    Report Objectives

    • To define, describe, and forecast the veterinary biologics market by product type, animal type, route of administration, application, end user, and region.
    • To provide detailed information about the key factors, such as drivers, restraints, opportunities, challenges, and industry trends, influencing the market growth
    • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI on veterinary biologics market, case study analysis, adjacent market analysis, unmet needs/end user expectations in veterinary biologics market, and trends/disruption impacting customer business in the market
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To strategically analyze the market in five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market

     

    Get the Full Veterinary Biologics Market Report

    Full forecast, segment splits, and company analysis for all Veterinary Biologics Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status